NCT04957901Recruiting
The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study
Source: ClinicalTrials.gov · Last updated 11 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The next-generation sequencing (NGS) based on liquid biopsy has been an emerging technology to identify tumor-specific genetic aberrations in malignant tumors. The tumor tissue (FFPE) and plasma samples from the newly diagnosed pediatric lymphoma patients were collected and sequenced by 475 genes panel before, during and post treatment, to evaluate the significance of the ctDNA in efficacy prediction, predicting recurrence or mechanism of resistance to chemotherapy for pediatric lymphoma.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 5 Jul 2021
- Start date
- 1 Dec 2021
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Childhood cancers
- NCT number
- NCT04957901
What you commit to
- Study type: Observational
- Planned participants: 60
- From 1 Dec 2021 to the primary completion date, 1 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients with any of the following items will not be enrolled in this study:
- Incomplete baseline samples (preoperative plasma samples, tissue, bone marrow, cerebrospinal fluid) due to various reasons;
- The follow-up samples cannot be obtained during the monitoring process;
- The researcher considered it unsuitable for enrollment.
Who the study is looking for
- Children with pediatric lymphoma (HL and NHL) that met the criteria and required treatment upon histological and pathological diagnosis;
- Age: \< 18 years old;
- The working status of the Eastern Cooperative Oncology Group (ECOG) (PS) : 0-2 points;
- CT/MRI measurable lesion was defined as the longest diameter of at least 1 lymph node ≥ 1.5cm, and it was clearly measurable in 2 vertical directions;
- Complete clinical laboratory examination and pathological examination information;
- Patients can be evaluated on time, and the required samples can be obtained throughout the testing process;
- After the patient is informed of the project, the informed consent signed by the patient or his legal representative is obtained.
Age in the registry: 1 year to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yizhuo Zhang Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.